脑脉泰胶囊治疗血管性痴呆41例

Clinical Effect of Naomaitai Capsule on Vascular Dementia Patients

摘要:

目的: 探讨脑脉泰胶囊对血管性痴呆轻、中度患者临床疗效及认知功能障碍的作用。 方法: 将82例血管性痴呆患者随机分为观察组和对照组各41例。观察组给予脑脉泰胶囊(2粒,3次/d,)口服,对照组给予脑复康(2片,3次/d)口服,疗程均为12周。评价两组的临床疗效及治疗前后简易精神状况检查量表(MMSE)评分和常见相关电位(P₃₀₀)检测结果的变化情况。 结果: 治疗12周后,两组疗效优于对照组,差异有统计学意义(P<0.05),两组治疗后MMSE评分、P₃₀₀潜伏期及P₃₀₀波幅较治疗前明显改善(P<0.05或P<0.01),且观察组优于对照组(P<0.05)。 结论: 脑脉泰胶囊治疗轻、中度血管性痴呆有较好的疗效,不良反应少,且能促进认知功能障碍的恢复。

Abstract:

Objective: To study the effect of Naomaitai capsule on cognitive dysfunction of vascular dementia patients. Method: Eighty four vascular dementia patients were randomly divided into therapeutic group and control group (n=41 each). The therapeutic group was treated by Naomaitai capsule (2 capsules, tid) and the control group by Naofukang (2 tablets, tid). The therapeutic course was 12 weeks. Before and after treatment, mimi-mental state examination (MMSE) grade and variation of frenquently appeared potential (P₃₀₀) were evaluated. Clinical efficacy was evaluated for the two groups. Result: After the therapeutic course, the total efficacy of the observation group was better than that of the control group, the difference was statistically significant (p<0.05). In two groups MMSE scores, P₃₀₀ latency and P₃₀₀ amplitude was significantly improved after treatment compared with those before treatment (P<0.05 or P<0.01). The improvement in the treatment group was better than that in the controls. Conclusion: Naomaitai capsule for treating vascular dementia shows good efficacy and less adverse reactions. The capsule can promote cognitive recovery.